GHP / Q3 2021 3 Contents , Welcome to the 2021 Q3 edition of Global Health & Pharma Magazine, providing you with all the latest news and features from across the healthcare and pharmaceutical landscape. As we come towards the final quarter of a second year shaped by a global pandemic, we might be excused for thinking only on the exceptional work around Covid-19 when reflecting on the successes achieved by the healthcare and pharmaceutical industries this year. However, over the last quarter, the global companies within these vital sectors have remained just as – if not more – busy with endeavours outside the pandemic as well. From the ground-breaking personalisation technology within breast cancer treatment being developed by DCISionRT, to VativoRx’s commitment to raising the standards in Pharmacy Benefit Management, to the many other stories of exceptional and transformational work exhibited in this issue of GHP Magazine, it is clear that the global health and pharmaceutical industry has a lot to be proud of this quarter. Thus, we invite you to dive in and discover more about these fantastic companies and their life-changing work – whether it be in aesthetic treatments or surgical procedures, pharmaceutical innovations or enhanced services. We hope you enjoy this issue of GHP Magazine and wish you safe and well until we meet again in the Q4 edition. Alex Abraham, Editor Website: www.ghp-news.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.